OrthoPediatrics (NASDAQ:KIDS) Given “Hold” Rating at Truist Financial

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “hold” rating reiterated by research analysts at Truist Financial in a research note issued to investors on Friday, Benzinga reports. They currently have a $34.00 price objective on the stock, up from their previous price objective of $30.00. Truist Financial’s target price indicates a potential upside of 5.33% from the stock’s previous close.

Several other brokerages have also recently issued reports on KIDS. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price objective on shares of OrthoPediatrics in a report on Friday.

OrthoPediatrics Trading Up 2.2 %

KIDS stock opened at $32.28 on Friday. The company has a market capitalization of $781.50 million, a price-to-earnings ratio of -33.63 and a beta of 1.18. OrthoPediatrics has a 1-year low of $23.10 and a 1-year high of $36.23. The business has a 50 day simple moving average of $30.84 and a two-hundred day simple moving average of $30.12. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.90 and a quick ratio of 1.96.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. The business had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $52.40 million. OrthoPediatrics had a negative return on equity of 5.44% and a negative net margin of 14.35%. Research analysts anticipate that OrthoPediatrics will post -0.96 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $29.30, for a total value of $293,000.00. Following the completion of the sale, the general counsel now directly owns 77,304 shares in the company, valued at $2,265,007.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 31.80% of the stock is owned by corporate insiders.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new stake in shares of OrthoPediatrics during the second quarter worth $34,000. EntryPoint Capital LLC lifted its position in shares of OrthoPediatrics by 56.9% during the first quarter. EntryPoint Capital LLC now owns 2,783 shares of the company’s stock worth $81,000 after purchasing an additional 1,009 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of OrthoPediatrics during the second quarter worth $110,000. State Board of Administration of Florida Retirement System bought a new stake in shares of OrthoPediatrics during the first quarter worth $178,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of OrthoPediatrics during the second quarter worth $203,000. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.